Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: kha vu who wrote (111785)	8/14/2000 8:35:23 AM
From: lee kramer	Read Replies (1) \| Respond to of 120523

Kha vu: Nice trade. Pre-market often terrific for getting in or out on amateur buying/selling. (Lee)

To: kha vu who wrote (111785)	8/14/2000 8:37:13 AM
From: Jerry Olson	Read Replies (3) \| Respond to of 120523

Kha we called NTAP as buy trigger in the room on Fri, and i said to hold it over the weekend..a 95 print could explode this stock... whooopie!!!! we be in da room<G> OJ

To: kha vu who wrote (111785)	8/14/2000 2:15:03 PM
From: Ron	Read Replies (1) \| Respond to of 120523

IMCL, interesting news: RESEARCH ALERT-Prospects of ImClone drug improved - Prudential NEW YORK, Aug 14 (Reuters) - Prudential Securities analyst Robert Toth said on Monday that prospects for ImClone Systems Inc.'s (NasdaqNM:IMCL - news) experimental cancer drug C225 have improved following a ``positive'' meeting last week between U.S. regulators and executives of the biotech company. -- Said officials of the U.S. Food and Drug Administration met with ImClone executives on Aug. 11 to discuss C225, adding the agency decided to allow the company to seek marketing approval of the drug for refractory colorectal cancer. -- Said the positive outcome of the FDA meeting indicates C225 could be on the market by late 2001, as much as 18 months before other medicines that also target various types of cancer by blocking a protein called epidermal growth factor receptor (EGF). -- ``We continue to believe that C225 has blockbuster potential and now is further assured of a possible first-to-market advantage in the attractive EGF Inhibitor cancer market,'' Toth said in a research report. -- Said the FDA meeting was a standard formal discussion in which ImClone and agency officials discussed how the company should proceed in seeking U.S. marketing approval of C225. The drug is a monoclonal antibody now in trials for patients with colorectal cancer who have failed other therapies. It is also being tested in two other trials against head and neck cancer and against pancreatic cancer. -- Toth said in an interview he believed C225, if approved, could garner eventual annual sales of $1 billion. He said at least 200,000 of an estimated 1.2 million Americans with colorectal cancer have failed to respond to standard current therapies and might possibly benefit from the ImClone drug. Shares of ImClone were up 11-1/4 to 81-3/4 on the Nasdaq in early afternoon trade.